Skip to main content
Premium Trial:

Request an Annual Quote

Genetix to Buy Cell-Imaging Company Applied Imaging for $18.3M

NEW YORK (GenomeWeb News) – Genetix Group today said it plans to acquire Applied Imaging, a maker of automated imaging and image-analysis systems, for $18.3 million in cash.
 
Genetix is based in New Milton, on the southern coast of England. The company designs, develops, and manufactures technologies involved in a wide array of cell screening, genomic, and proteomic applications.
 
Applied Imaging, based in San Jose, Calif., sells instruments for cytogenetic testing, among other applications. Genetix is hoping that the acquisition will expand its cell-imaging and -analysis play and boost its presence in the US.
 
“Genetix's cell biology instruments and reagents complement Applied Imaging's imaging and image analysis systems and will help both companies to expand in the US, Europe, and Asia," added Genetix CEO Mark Reid.
 
Terms of the deal call for Genetix to pay $3.06 per share to acquire all of Applied Imaging's common stock. The transaction is expected to close in the fourth quarter.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.